Non Small Cell Lung Cancer News and Research

RSS

Non-Small Cell Lung Cancers are a group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Non-small cell lung cancer is the most common kind of lung cancer.

RYBREVANT Receives EC Nod for Advanced Lung Cancer Treatment

Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved a Type II extension of indication for RYBREVANT®▼ (amivantamab) in combination with chemotherapy (carboplatin and pemetrexed), for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 19 deletions (ex19del) or Exon 21 L858R substitution (L858R) mutations, after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI).

30 Aug 2024

Breakthrough Study Reveals Role of Tissue-Resident Memory T Cells in Lung Cancer Prognosis

An extensive analytical study performed at the Terasaki Institute and published in Frontiers in Immunology highlights the crucial role of tissue-resident memory T cells and how they influence the immune environment of patients with non-small cell lung cancer and their overall prognosis.

1 Aug 2024

Genomic Deletions Drive Development of Melanoma Drug Resistance

Melanoma is the deadliest form of skin cancer. With global incidence rates rising, new, more effective treatments are necessary to alleviate the health burden of the disease. Important advances in recent years include doctors using genetic tests to look for specific mutations they can target for more personalised, effective treatment.

15 Apr 2024

Novel Gene Signature Identified for Predicting Immunotherapy Response in NSCLC

A new study identified a set of 140 genes that may help predict enhanced disease-free survival in patients with non-small cell lung cancer (NSCLC) treated with a combination of immunotherapy and low-dose radiation.

26 Feb 2024

Researchers Target Pancreatic Cancer’s Metabolic Switch

In a recent study, a novel combination of treatments was discovered to effectively reduce the growth of pancreatic cancer in mice by inhibiting cancer cells from seeking fuel sources.

11 Oct 2023

Understanding the Role of T Cells in Lung Cancer Could Lead to Improved Immunotherapy Outcomes

Fresh discoveries about a type of immune cells could give lung cancer patients a more accurate prognosis and better identify who will benefit from immunotherapies.

31 Aug 2023

New Findings May Provide Useful Therapeutic Approach for Treating Breast Cancer Patients

A new editorial paper was published in Oncotarget's Volume 14 on June 12, 2023, entitled, "Are cis-spliced fusion proteins pathological in more aggressive luminal breast cancer?"

21 Aug 2023

Insights into mechanisms impacting NSCLC disease progression

Proteomics is the study and analysis of proteins in a biological system, including their structures, functions, associations, and alterations.

5 Apr 2023

Neoadjuvant dual immunotherapy and chemotherapy improve outcomes in patients with resectable NSCLC

In a Phase II trial led by researchers from The University of Texas MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant, or pre-surgical, combination of nivolumab plus platinum-based chemotherapy, resulted in a major pathologic response (MPR) in half of all treated patients with early-stage, resectable non-small cell lung cancer (NSCLC).

20 Mar 2023

Using PET and electron microscopy to generate 3D maps of mitochondrial networks in lung tumors

Scientists have long known that mitochondria, the "powerhouses" of cells, play a crucial role in the metabolism and energy production of cancer cells.

16 Mar 2023

Strata Oncology publishes study validating integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit

Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced the publication of a new peer-reviewed study validating the clinical utility of the company's proprietary pan-solid tumor predictive biomarker for anti-PD-1/PD-L1 checkpoint inhibitor monotherapy benefit, Immunotherapy Response Score (IRS).

8 Feb 2023

Researchers analyze the significance of cellular interactions for lung cancer

A new Cleveland Clinic study has uncovered vital information about the cellular interaction of tumor cells and normal tissue, leading to a better understanding of how therapeutic resistance evolves.

5 Jul 2022

Researchers created ultrasound-guided microbubbles to enhance immunotherapy performance

The University of Texas MD Anderson Cancer Center scientists have created an ultrasound-guided cancer immunotherapy approach that promotes systemic antitumor immunity and increases immune checkpoint blockade therapeutic potential. Nature Nanotechnology published the results of the pioneering study.

1 Jun 2022

Epigenetic regulator helps determine lung cancer patients and their resistance to drugs

Doctors commonly use tyrosine kinase inhibitors, particularly epidermal growth factor receptor inhibitors, to cure patients with non-small cell lung cancer, a common and typically deadly kind of cancer that accounts for 80% to 85% of lung cancers.

20 Apr 2022

ATM kinase inhibitor combines with target therapies to wipe out cancer cells

While cancer therapies that target specific genes or disease pathways might prolong life span, they can also result in highly resistant tumors when tiny reservoirs of cancer cells survive therapy, develop, and spread.

1 Apr 2022

Study identifies genes that protect ovarian cancer from antitumor immunity

Immunotherapies are exhibiting better clinical benefit in the treatment of numerous cancers, particularly when used along with chemotherapy.

2 Dec 2021

New model for early prediction of cancer patients' response to immunotherapy

Researchers have developed a model that could predict early on in treatment whether cancer patients will respond to immunotherapy, according to a report published today in eLife.

10 Nov 2021

Study reveals what causes T cells to be non-responsive to immunotherapy

Non-small cell lung cancer is the most common type of lung cancer in humans. Some patients with NSCLC receive a therapy called immune checkpoint blockade (ICB) that helps kill cancer cells by reinvigorating a subset of immune cells called T cells, which are "exhausted" and have stopped working.

1 Nov 2021

Researchers find a new way to counter immunosuppressive effect in tumors

Malignant tumors can enhance their ability to survive and spread by suppressing antitumor immune cells in their vicinity, but a study led by researchers at Weill Cornell Medicine and NewYork-Presbyterian has uncovered a new way to counter this immunosuppressive effect.

21 Sep 2021

Vaccinating against certain cancer proteins can boost overall immune response and shrink tumors

Over the past decade, scientists have been exploring vaccination as a way to help fight cancer. These experimental cancer vaccines are designed to stimulate the body's own immune system to destroy a tumor, by injecting fragments of cancer proteins found on the tumor.

17 Sep 2021